Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264564 | 0.82 | LTA4H (0.57) | POLBMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL5381777 | 0.82 | LTA4H (0.54) | POLBMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL1928086 | 0.79 | HRH3 (0.56) | SMN1; SMN2MAPTHPGDNPC1CYP1A2 | |
| SCHEMBL6313154 | 0.79 | ALDH1A1 (0.59) | MEN1KMT2ASMN1; SMN2MAPTHPGD | |
| SCHEMBL10208004 | 0.79 | POLB (0.50) | POLBMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL12519500 | 0.78 | POLB (0.63) | POLBMEN1KMT2AHPGDNPC1 | |
| SCHEMBL31378757 | 0.78 | HRH3 (0.55) | SMN1; SMN2MAPTHPGDNPC1CYP1A2 | |
| SCHEMBL5381533 | 0.78 | MAPT (0.49) | MEN1KMT2ASMN1; SMN2MAPTHPGD | |
| SCHEMBL1929880 | 0.77 | LTA4H (0.57) | POLBMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL2086647 | 0.77 | KMT2A (0.61) | MEN1KMT2ASMN1; SMN2MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618115-B2 | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2298776-A1 | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298776-A1 | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1948665-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007050726-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050726-A2 | THIENOPYRIMIDINONE DERIVATIVES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | POLB 3995/4885MEN1 512/4885KMT2A 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.